ArticleOncotarget2018

Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma.

Jian Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.